Search
00
GBAF Logo
trophy
Top StoriesInterviewsBusinessFinanceBankingTechnologyInvestingTradingVideosAwardsMagazinesHeadlinesTrends

Subscribe to our newsletter

Get the latest news and updates from our team.

Global Banking & Finance Review®

Global Banking & Finance Review® - Subscribe to our newsletter

Company

    GBAF Logo
    • About Us
    • Profile
    • Privacy & Cookie Policy
    • Terms of Use
    • Contact Us
    • Advertising
    • Submit Post
    • Latest News
    • Research Reports
    • Press Release
    • Awards▾
      • About the Awards
      • Awards TimeTable
      • Submit Nominations
      • Testimonials
      • Media Room
      • Award Winners
      • FAQ
    • Magazines▾
      • Global Banking & Finance Review Magazine Issue 79
      • Global Banking & Finance Review Magazine Issue 78
      • Global Banking & Finance Review Magazine Issue 77
      • Global Banking & Finance Review Magazine Issue 76
      • Global Banking & Finance Review Magazine Issue 75
      • Global Banking & Finance Review Magazine Issue 73
      • Global Banking & Finance Review Magazine Issue 71
      • Global Banking & Finance Review Magazine Issue 70
      • Global Banking & Finance Review Magazine Issue 69
      • Global Banking & Finance Review Magazine Issue 66
    Top StoriesInterviewsBusinessFinanceBankingTechnologyInvestingTradingVideosAwardsMagazinesHeadlinesTrends

    Global Banking & Finance Review® is a leading financial portal and online magazine offering News, Analysis, Opinion, Reviews, Interviews & Videos from the world of Banking, Finance, Business, Trading, Technology, Investing, Brokerage, Foreign Exchange, Tax & Legal, Islamic Finance, Asset & Wealth Management.
    Copyright © 2010-2026 GBAF Publications Ltd - All Rights Reserved. | Sitemap | Tags | Developed By eCorpIT

    Editorial & Advertiser disclosure

    Global Banking & Finance Review® is an online platform offering news, analysis, and opinion on the latest trends, developments, and innovations in the banking and finance industry worldwide. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.

    Home > Top Stories > U.S. could control COVID by spring 2022 if more people get shots – Fauci
    Top Stories

    U.S. could control COVID by spring 2022 if more people get shots – Fauci

    Published by maria gbaf

    Posted on August 25, 2021

    6 min read

    Last updated: January 21, 2026

    Dr. Anthony Fauci emphasizes the importance of increasing COVID-19 vaccinations to control the pandemic by spring 2022 during a press briefing. This image relates to the urgent call for more vaccinations and potential FDA approvals.
    Dr. Anthony Fauci discussing COVID-19 vaccinations during a press conference - Global Banking & Finance Review
    Why waste money on news and opinion when you can access them for free?

    Take advantage of our newsletter subscription and stay informed on the go!

    Subscribe

    By Susan Heavey and Carl O’Donnell

    WASHINGTON (Reuters) – The United States could get COVID-19 under control by early next year if vaccinations ramp up, Dr. Anthony Fauci said on Tuesday, one day after Pfizer won fuller FDA approval for its shot, with more potential approvals coming in the weeks ahead.

    Fauci, the nation’s top infectious disease expert, said in multiple television interviews and a White House press conference that full Food and Drug Administration approval for the Pfizer-BioNTech vaccine paves the way for more people to get inoculated https://tmsnrt.rs/3tUM8ta, with potential approval for Moderna Inc’s in the coming weeks and authorization for younger children by autumn.

    “I would like to appeal to the people in the country who are not vaccinated to realize that we have the capability, among ourselves, to essentially cut down the time frame to getting to the end of this pandemic,” Fauci, head of the National Institutes of Allergy and Infectious Diseases, said during a Tuesday press conference.

    “I think there’s a reasonable chance” that Pfizer or Moderna could get FDA clearance for children under 12 before the upcoming holiday season, he told NBC News. “Hopefully by the mid-late fall and early winter.”

    U.S. officials during the Tuesday press briefing also urged private employers and more state and local governments to require staff to get vaccinated in a bid to drive up vaccination rates.

    “Now is the time” for U.S. employers to start mandating vaccinations, White House COVID coordinator Jeffrey Zients said, echoing remarks from President Joe Biden on Monday.

    Meanwhile, the White House is preparing to provide third “booster” doses starting in mid-September to Americans who received their COVID-19 inoculation more than eight months ago. The plan depends upon a thumbs up from the FDA and an advisory panel to the CDC.

    “We want to make sure we stay ahead of the virus,” Zients said, adding that “the plan is pending the FDA conducting an independent evaluation and outside experts… issuing a booster dose recommendation.”

    Fauci added that healthcare providers should also make more use of COVID-19 antibody treatments, including those from Eli Lilly & Co, Regeneron Pharmaceuticals, and GlaxoSmithKline Plc/Vir Biotechnology Inc. Such treatments can reduce hospitalizations and deaths by as much as 85% if used early in infected people, he said.

    The United States is battling another wave of cases https://tmsnrt.rs/2WkNEK5 due to the highly contagious Delta variant. Hospitalizations and deaths are also rising, particularly in Florida, Mississippi, Louisiana, Texas and other parts of the U.S. South.

    The average number of deaths from COVID-19 has risen by 23% over the previous seven-day period, Dr. Rochelle Walensky, director of the U.S. Centers for Disease Control and Prevention, during a Tuesday press call. The United States is now averaging 1,000 COVID deaths a day and over 150,000 new cases, according to a Reuters tally.

    U.S. health officials have also noted the number of inoculations has also risen in recent weeks and say they hope Monday’s FDA action spurs more people get their first shots.

    The U.S. military, along with several businesses and universities, including CVS Health Corp, privately held Deloitte and at least one college football team, have moved ahead with COVID vaccine mandates since the FDA’s announcement, which also buoyed Wall Street.

    (Reporting by Susan Heavey and Carl O’Donnell; additional reporting by Lisa Lambert; Editing by Dan Grebler and Lisa Shumaker)

    By Susan Heavey and Carl O’Donnell

    WASHINGTON (Reuters) – The United States could get COVID-19 under control by early next year if vaccinations ramp up, Dr. Anthony Fauci said on Tuesday, one day after Pfizer won fuller FDA approval for its shot, with more potential approvals coming in the weeks ahead.

    Fauci, the nation’s top infectious disease expert, said in multiple television interviews and a White House press conference that full Food and Drug Administration approval for the Pfizer-BioNTech vaccine paves the way for more people to get inoculated https://tmsnrt.rs/3tUM8ta, with potential approval for Moderna Inc’s in the coming weeks and authorization for younger children by autumn.

    “I would like to appeal to the people in the country who are not vaccinated to realize that we have the capability, among ourselves, to essentially cut down the time frame to getting to the end of this pandemic,” Fauci, head of the National Institutes of Allergy and Infectious Diseases, said during a Tuesday press conference.

    “I think there’s a reasonable chance” that Pfizer or Moderna could get FDA clearance for children under 12 before the upcoming holiday season, he told NBC News. “Hopefully by the mid-late fall and early winter.”

    U.S. officials during the Tuesday press briefing also urged private employers and more state and local governments to require staff to get vaccinated in a bid to drive up vaccination rates.

    “Now is the time” for U.S. employers to start mandating vaccinations, White House COVID coordinator Jeffrey Zients said, echoing remarks from President Joe Biden on Monday.

    Meanwhile, the White House is preparing to provide third “booster” doses starting in mid-September to Americans who received their COVID-19 inoculation more than eight months ago. The plan depends upon a thumbs up from the FDA and an advisory panel to the CDC.

    “We want to make sure we stay ahead of the virus,” Zients said, adding that “the plan is pending the FDA conducting an independent evaluation and outside experts… issuing a booster dose recommendation.”

    Fauci added that healthcare providers should also make more use of COVID-19 antibody treatments, including those from Eli Lilly & Co, Regeneron Pharmaceuticals, and GlaxoSmithKline Plc/Vir Biotechnology Inc. Such treatments can reduce hospitalizations and deaths by as much as 85% if used early in infected people, he said.

    The United States is battling another wave of cases https://tmsnrt.rs/2WkNEK5 due to the highly contagious Delta variant. Hospitalizations and deaths are also rising, particularly in Florida, Mississippi, Louisiana, Texas and other parts of the U.S. South.

    The average number of deaths from COVID-19 has risen by 23% over the previous seven-day period, Dr. Rochelle Walensky, director of the U.S. Centers for Disease Control and Prevention, during a Tuesday press call. The United States is now averaging 1,000 COVID deaths a day and over 150,000 new cases, according to a Reuters tally.

    U.S. health officials have also noted the number of inoculations has also risen in recent weeks and say they hope Monday’s FDA action spurs more people get their first shots.

    The U.S. military, along with several businesses and universities, including CVS Health Corp, privately held Deloitte and at least one college football team, have moved ahead with COVID vaccine mandates since the FDA’s announcement, which also buoyed Wall Street.

    (Reporting by Susan Heavey and Carl O’Donnell; additional reporting by Lisa Lambert; Editing by Dan Grebler and Lisa Shumaker)

    More from Top Stories

    Explore more articles in the Top Stories category

    Image for Lessons From the Ring and the Deal Table: How Boxing Shapes Steven Nigro’s Approach to Banking and Life
    Lessons From the Ring and the Deal Table: How Boxing Shapes Steven Nigro’s Approach to Banking and Life
    Image for Joe Kiani in 2025: Capital, Conviction, and a Focused Return to Innovation
    Joe Kiani in 2025: Capital, Conviction, and a Focused Return to Innovation
    Image for Marco Robinson – CLOSE THE DEAL AND SUDDENLY GROW RICH
    Marco Robinson – CLOSE THE DEAL AND SUDDENLY GROW RICH
    Image for Digital Tracing: Turning a regulatory obligation into a commercial advantage
    Digital Tracing: Turning a regulatory obligation into a commercial advantage
    Image for Exploring the Role of Blockchain and the Bitcoin Price Today in Education
    Exploring the Role of Blockchain and the Bitcoin Price Today in Education
    Image for Inside the World’s First Collection Industry Conglomerate: PCA Global’s Platform Strategy
    Inside the World’s First Collection Industry Conglomerate: PCA Global’s Platform Strategy
    Image for Chase Buchanan Private Wealth Management Highlights Key Autumn 2025 Budget Takeaways for Expats
    Chase Buchanan Private Wealth Management Highlights Key Autumn 2025 Budget Takeaways for Expats
    Image for PayLaju Strengthens Its Position as Malaysia’s Trusted Interest-Free Sharia-Compliant Loan Provider
    PayLaju Strengthens Its Position as Malaysia’s Trusted Interest-Free Sharia-Compliant Loan Provider
    Image for A Notable Update for Employee Health Benefits:
    A Notable Update for Employee Health Benefits:
    Image for Creating Equity Between Walls: How Mohak Chauhan is Using Engineering, Finance, and Community Vision to Reengineer Affordable Housing
    Creating Equity Between Walls: How Mohak Chauhan is Using Engineering, Finance, and Community Vision to Reengineer Affordable Housing
    Image for Upcoming Book on Real Estate Investing: Harvard Grace Capital Founder Stewart Heath’s Puts Lessons in Print
    Upcoming Book on Real Estate Investing: Harvard Grace Capital Founder Stewart Heath’s Puts Lessons in Print
    Image for ELECTIVA MARKS A LANDMARK FIRST YEAR WITH MAJOR SENIOR APPOINTMENTS AND EXPANSION MILESTONES
    ELECTIVA MARKS A LANDMARK FIRST YEAR WITH MAJOR SENIOR APPOINTMENTS AND EXPANSION MILESTONES
    View All Top Stories Posts
    Previous Top Stories PostDelta blow knocks wind out of Asia’s economic recovery
    Next Top Stories PostU.S. companies including Airbnb, Walmart pitch in on Afghanistan aid